Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
9/10/2026
-
Tickeron - Stocks
9/9/2026
-
Tickeron - Stocks
9/6/2026
-
Tickeron - Stocks
9/6/2026
-
Tickeron - Stocks
9/4/2026
-
Tickeron - Stocks
9/4/2026
-
Tickeron - Stocks
9/4/2026
-
MarketBeat
9/4/2026
-
Tickeron - Stocks
9/4/2026
-
Tickeron - Stocks
Galectin Therapeutics (GALT, $4.48) price may drop as it broke higher Bollinger Band on Sep 02, 2026
9/3/2026
-
Tickeron - Stocks
9/2/2026
-
Tickeron - Stocks
8/29/2026
-
Tickeron - Stocks
8/27/2026
-
Tickeron - Stocks
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average - Here's What Happened
8/27/2026
-
MarketBeat
8/18/2026
-
MarketBeat
8/15/2026
-
Tickeron - Stocks
8/14/2026
-
The Cerbat Gem
8/14/2026
-
MarketBeat
8/14/2026
-
Globe Newswire
8/13/2026
-
MarketBeat
8/13/2026
-
Tickeron - Stocks
8/7/2026
-
TipRanks
8/6/2026
-
MarketBeat
8/4/2026
-
TipRanks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, August 14, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 9 and 13 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
678 620 3186
Address
4960 Peachtree Industrial Boulevard
Suite 240
Norcross, GA 30071
Suite 240
Norcross, GA 30071
Country
Year Founded
Business Description
Sector
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate...
more